Document is current
Any future updates will be listed below
-
Authors
Slatton, J.
Jiminez, V.
Beam, J.
Rademacher, N.
Montgomery, K.
Bateni, S.
Broman, K. https://orcid.org/0000-0002-4679-4665
- License Information
-
More Information
Article History
First Online: 2 March 2026
IRB statement
: The study was approved by the Institutional Review Board at the University of Alabama at Birmingham (IRB #300006558).
: This retrospe ctive cohort study analyzed the patient characteristics and outcomes of individuals receiving Talimogene Laherparepvec in an off label indication for non melanoma skin cancers.
